The lining of a healthy artery is one cell thick, yet that single layer decides how well blood moves through the body. Cardiologists have a way to watch it work in real time — they inflate a cuff on the forearm, release it, and measure how much the artery widens as blood rushes back. That measurement is called flow-mediated dilation, and for three decades it has been the closest thing vascular medicine has to a live readout of endothelial health. What most explainers skip is where the trail leads next: the same biology that flow-mediated dilation measures is nitric-oxide and redox dependent, and a separate body of research — molecular hydrogen — has been probing exactly that intersection for close to two decades.
This is a piece about hydrogen water and endothelial function: what the vascular research actually shows and where the human signals are. Flow-mediated dilation is the on-ramp. Molecular hydrogen is the destination.
What Flow-Mediated Dilation Measures — and Why It Matters
Flow-mediated dilation, usually shortened to FMD, is a non-invasive ultrasound test. A clinician measures the diameter of an artery in the arm, occludes blood flow with a cuff for several minutes, then releases it and watches the vessel respond. When blood surges back, a healthy endothelium senses the shear stress and signals the artery to widen. The percentage increase in diameter is the FMD score. Higher is generally read as healthier vascular function.
The Brachial Artery Test
The vessel most often used is in the upper arm (the brachial artery, specifically), chosen because it is accessible and its behavior correlates with the coronary arteries clinicians actually worry about. The test is elegant in its logic. It does not measure the plumbing directly; it measures whether the lining can still do its job of translating a change in blood flow into a change in vessel width. A reading of six or seven percent is unremarkable in a healthy adult. Values drift downward with age, smoking, high glucose, and the other pressures that accumulate across a life, which is why researchers treat FMD as a running index of vascular aging rather than a single verdict. What makes the test valuable to epidemiologists is that a low FMD tends to show up years before an overt cardiovascular event, which lets it function as an early warning rather than a post-mortem. It is a window onto a process, not a snapshot of a moment.
The Redox Dependence of Endothelial Function
Here is the pivot that most FMD explainers never make. The reason a healthy artery widens on cue is a small, unstable molecule called nitric oxide, produced by the endothelial cells themselves. When shear stress rises, those cells release nitric oxide, the surrounding smooth muscle relaxes, and the vessel opens. Endothelial function, measured by FMD, is in large part a measurement of how much bioavailable nitric oxide the lining can muster on demand.
Nitric Oxide and the Endothelium
Nitric oxide is exquisitely sensitive to its chemical environment. It has a half-life measured in seconds, and one of the fastest ways to destroy it is to expose it to a specific reactive species. When superoxide meets nitric oxide, the two react to form peroxynitrite — a damaging oxidant — and the nitric oxide that would have relaxed the vessel is simply gone before it can act. So the endothelium's ability to dilate is not only about how much nitric oxide it makes. It is equally about how much survives the trip. Two vessels can produce identical amounts of nitric oxide and behave completely differently, simply because one of them is sitting in a more oxidizing environment that consumes the signal before it can act. That is the subtlety the FMD number quietly folds together — production and survival, in a single reading.
How Oxidative Stress Degrades the Signal
Oxidative stress is the name researchers give to the imbalance that arises when the production of reactive oxygen species outpaces the antioxidant systems built to keep them in check. In the vessel wall, that imbalance has a direct and well-mapped consequence: nitric oxide gets scavenged before it can widen the artery, and endothelial function measurably declines. A great deal of vascular research on FMD is, underneath the surface, research on the redox balance of the endothelium. That is the door through which molecular hydrogen research enters: if a molecule could interact with the most damaging reactive species without flattening the useful signaling ones, the endothelium is a tissue where researchers would look. Our overview of nitric oxide and vascular health walks through this signaling chain in more depth.
Where Molecular Hydrogen Entered the Vascular Conversation
One paper moved molecular hydrogen from the fringe into an active research field. Ohsawa and colleagues, writing in Nature Medicine in 2007, reported that molecular hydrogen selectively reduced the hydroxyl radical and peroxynitrite in their experiments — the most cytotoxic reactive species — while leaving alone the reactive oxygen species that carry out useful physiological signaling [1]. Their model was a rat stroke experiment, not a human vascular trial, and the authors framed the finding as a hypothesis to be tested rather than a settled fact. Its relevance to the endothelium is hard to miss, though. Peroxynitrite is the very species that destroys nitric oxide in the vessel wall.
The Selective Antioxidant Hypothesis
Molecular hydrogen is small, electrically neutral, and diffusible. Researchers have proposed that these properties let it reach compartments larger antioxidant molecules struggle to enter — across membranes, into the cell interior where nitric oxide and superoxide meet. A working framework, still under investigation. The distinction the field keeps returning to is selectivity: an antioxidant that suppressed every reactive species equally would blunt the useful signaling alongside the damaging kind, which is not obviously desirable. Hong and colleagues, reviewing the clinical and experimental literature in The Journal of International Medical Research in 2010, described this selective antioxidant framework as promising but still under investigation rather than established [10]. For readers who want the contrast spelled out, our piece comparing selective and non-selective free-radical strategies covers why the difference matters.
The Human FMD Signal Researchers Reported
The most direct link between molecular hydrogen and the FMD test comes from a small 2014 study. Sakai and colleagues, publishing in Vascular Health and Risk Management, examined whether water containing a high concentration of dissolved hydrogen was associated with a change in flow-mediated dilation [2]. They reported that consumption of water carrying over 3.5 milligrams of dissolved hydrogen was associated with an increase in FMD, with the measured value moving from roughly 6.80 percent to 7.64 percent in their participants. The researchers raised the possibility of a nitric-oxide-mediated vasodilation mechanism — the exact pathway the redox story predicts.
The High-Concentration Threshold
The detail worth holding onto is the concentration. Sakai and colleagues did not report a signal from ordinary hydrogen water; the association they observed was tied specifically to high-concentration HRW, above that 3.5 milligram threshold. This is a recurring theme across the vascular literature — the amount of hydrogen actually dissolved in the water appears to matter, and low-concentration preparations may not resemble what the researchers studied. The trial itself was small, and the authors were explicit that a larger confirmation study would be needed before anyone should read too much into a single group. A signal, not a verdict.
The Endothelial-Function Randomized Controlled Trial
Six years later, a stronger study design took up the same question. Ishibashi and colleagues ran a randomized controlled trial, published in PLoS One in 2020, testing whether daily consumption of water containing over 7 parts per million of dissolved hydrogen affected peripheral endothelial function [3]. Rather than the brachial ultrasound of the FMD test, they used the reactive hyperemia index, or RHI, a related finger-based measure of how well small vessels dilate. The researchers reported that RHI improved over the study period in the group drinking high-concentration hydrogen-rich water.
Who Responded Most in the RCT
The pattern inside the data is the part clinicians find interesting. Ishibashi and colleagues reported that the improvement was most pronounced among participants whose baseline endothelial health was lower to begin with, and they raised the possibility of a dose-response relationship tied to how much dissolved hydrogen the water carried [3]. A subgroup responding more strongly than the pooled average is a familiar signature in this field — it points toward who might respond rather than settling whether anyone does, and it is exactly the kind of result that motivates the next, larger trial. The randomized design puts this study a notch above the 2014 work in evidentiary weight, though it too was modest in size. Among the clinical trials that speak most directly to endothelial function, these two carry the most weight.
How Deep the Hydrogen Research Base Runs
The volume of research is the part most people underestimate. Johnsen and colleagues, reviewing the clinical landscape in Molecules in 2023, identified 81 clinical trials reported across 64 publications, with positive signals reported in several areas including cardiovascular endpoints, all sitting inside a broader body of more than two thousand publications investigating molecular hydrogen [7].
What the Systematic Reviews Caution
Serious reviewers are careful, and so are we. Johnsen and colleagues noted that many of the underlying trials are small and heterogeneous, which limits how far any single result can be pushed [7]. Korovljev and colleagues, in a 2024 systematic review in the International Journal of Environmental Research and Public Health that asked bluntly whether hydrogen water is extra healthy or a hoax, reached a measured conclusion: they found genuine positive signals across several domains, but flagged that the evidence base is limited by small trials, widely variable hydrogen concentrations, and the absence of standardized protocols [8]. That is the honest state of the field — real signals, real limitations, and a clear need for larger and better-standardized studies. Our article asking directly whether hydrogen water is a scam works through the same tension without overselling either side.
The Cardiac and Cholesterol Trials Running in Parallel
The endothelial research did not develop alone. A cluster of cardiovascular trials has been running alongside it, and while none of them measured FMD directly, each touches the same vascular biology. Taken together they sketch the broader picture of cardiovascular disease risk that the endothelial signal sits inside — a picture our overview of hydrogen water and cardiovascular health lays out in full.
The STEMI Pilot in Humans
Katsumata and colleagues, publishing in Circulation Journal in 2017, ran the first human pilot of hydrogen gas inhalation after percutaneous coronary intervention for ST-elevation myocardial infarction [4]. The point of a first-in-human pilot is feasibility and safety, and on those terms the researchers reported the approach to be feasible and safe. They also observed a numerically greater left ventricular stroke volume index at six months in the hydrogen group — but they were candid that the difference did not reach statistical significance, and that the study was underpowered to establish anything of the sort. A first step, deliberately cautious. The value of a pilot like this is not the effect size; it is the demonstration that the intervention can be delivered safely in a fragile population and that a larger, properly powered trial is worth funding. The researchers said as much.
The Unstable Angina Adjunct Study
Si and colleagues, in Experimental Biology and Medicine in 2021, studied hydrogen as an adjuvant alongside standard care in people with unstable angina [5]. They reported greater reductions in total cholesterol, LDL cholesterol, and apolipoprotein B in the group receiving hydrogen in addition to standard treatment, compared with standard care alone. The authors described the findings as preliminary. Cholesterol and apolipoprotein B are core cardiovascular risk markers, so the direction of the signal is coherent with the broader story, even if the study is small and needs replication. Our deeper look at hydrogen water and cholesterol unpacks that specific line of research.
What the Preclinical Vascular Work Showed
Underneath the human trials sits a layer of animal research that first suggested the vascular angle was worth pursuing. It is useful to keep the evidentiary ladder straight here — an animal model generates hypotheses; it does not confirm human outcomes.
The ApoE Knockout Model
Ohsawa and colleagues, writing in Biochemical and Biophysical Research Communications in 2008, studied hydrogen water in apolipoprotein E knockout mice, a standard laboratory model used to study arterial plaque formation [6]. The researchers reported reduced plaque and lower aortic oxidative stress in the animals given hydrogen water. This is preclinical work in a mouse model, and its value is mechanistic: it links dissolved hydrogen to lower oxidative stress in arterial tissue, which is the same redox thread that runs through the endothelial-function trials in people. Suggestive, not conclusive. The gap between a mouse aorta and a human artery is exactly why the later human studies mattered so much.
Hydrogen, Vascular Aging, and Antioxidant Capacity
Endothelial function declines with age, and vascular aging is one of the frames researchers use to organize the whole subject. A healthy young endothelium mounts a brisk nitric-oxide response; an aged one, chronically exposed to oxidative stress, does so more weakly, and FMD scores fall accordingly. That is where the aging and antioxidant-capacity literature intersects with everything above.
Antioxidant Capacity and the Aging Vessel
Ge and colleagues, in a 2022 review in Oxidative Medicine and Cellular Longevity, surveyed the role of molecular hydrogen in aging and age-related conditions, drawing together work on telomere maintenance, cellular senescence, autophagy, mTOR signaling, and mitochondrial function [9]. The reviewers were clear that most of this is mechanistic data from animal models rather than human outcome trials. Still, the through-line is antioxidant capacity — the idea that the balance between reactive species and the systems that check them shifts with age, and that molecular hydrogen has been investigated as one anti-inflammatory and antioxidant input into that balance. Aging vessels tend to accumulate exactly the kind of chronic, low-grade oxidative pressure that erodes the nitric-oxide signal, so the aging frame and the endothelial frame are really the same story told on different timescales. What flow-mediated dilation captures in an afternoon, the aging literature captures across decades. For metabolic syndrome specifically, where oxidative stress, glucose dysregulation, and endothelial dysfunction tend to travel together, this framing is why so many of the cardiovascular trials recruited exactly that population. Our article on hydrogen water and anti-aging research collects that thread in one place.
Holy Hydrogen products, including the Lourdes Hydrofix Premium Edition, are not medical devices and are not intended to diagnose, treat, cure, or prevent any disease. All information on this site is provided for educational and general wellness purposes only and should not be considered medical advice. Always consult a qualified healthcare provider before beginning any new wellness practice, especially if you have a medical condition, are pregnant or nursing, or take prescription medications.
Further Reading
- Ohsawa I, Ishikawa M, Takahashi K, et al. Nature Medicine, 2007. PMID: 17486089. The paper that launched the modern field, proposing that molecular hydrogen acts selectively on the most damaging reactive species.
- Sakai T, et al. Vascular Health and Risk Management, 2014. PMID: 25378931. The small human study most directly tying high-concentration hydrogen water to a change in the flow-mediated dilation test.
- Ishibashi T, et al. PLoS One, 2020. PMID: 32470022. A randomized controlled trial of peripheral endothelial function, useful for seeing how a subgroup can respond more strongly than the pooled average.
- Johnsen HM, Hiorth M, Klaveness J. Molecules, 2023. PMID: 38067515. A wide-angle review inventorying the clinical trial landscape — the best single place to gauge how large this field has become.
- Korovljev D, Trivic T, Drid P, et al. International Journal of Environmental Research and Public Health, 2024. PMC: PMC10816294. A systematic review that weighs the genuine positive signals against the field's small trials and variable concentrations.
- Ge L, et al. Oxidative Medicine and Cellular Longevity, 2022. PMC: PMC8956398. A mechanism-focused review of molecular hydrogen in aging, for readers who want the cellular argument rather than a summary.
References
[1] Ohsawa I, Ishikawa M, Takahashi K, et al. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nature Medicine. 2007. PMID: 17486089
[2] Sakai T, et al. Consumption of water containing over 3.5 mg of dissolved hydrogen could improve vascular endothelial function. Vascular Health and Risk Management. 2014. PMID: 25378931
[3] Ishibashi T, et al. Peripheral endothelial function can be improved by daily consumption of water containing over 7 ppm of dissolved hydrogen: a randomized controlled trial. PLoS One. 2020. PMID: 32470022
[4] Katsumata Y, et al. The Effects of Hydrogen Gas Inhalation on Adverse Left Ventricular Remodeling After Percutaneous Coronary Intervention for ST-Elevated Myocardial Infarction. Circulation Journal. 2017. PMID: 28321000
[5] Si J, et al. Effects of hydrogen as adjuvant treatment for unstable angina. Experimental Biology and Medicine. 2021. PMID: 33899541
[6] Ohsawa I, Nishimaki K, Yamagata K, et al. Consumption of hydrogen water prevents atherosclerosis in apolipoprotein E knockout mice. Biochemical and Biophysical Research Communications. 2008. PMID: 18996093
[7] Johnsen HM, Hiorth M, Klaveness J. Molecular Hydrogen Therapy—A Review on Clinical Studies and Outcomes. Molecules. 2023. PMID: 38067515
[8] Korovljev D, Trivic T, Drid P, et al. Hydrogen Water: Extra Healthy or a Hoax? A Systematic Review. International Journal of Environmental Research and Public Health. 2024. PMC: PMC10816294
[9] Ge L, et al. Role of Molecular Hydrogen in Ageing and Ageing-Related Diseases. Oxidative Medicine and Cellular Longevity. 2022. PMC: PMC8956398
[10] Hong Y, et al. Hydrogen as a Selective Antioxidant: A Review of Clinical and Experimental Studies. The Journal of International Medical Research. 2010. PMID: 21226992
[11] Ichikawa H, et al. Molecular Hydrogen: A Therapeutic Antioxidant and Beyond. Medical Gas Research. 2017. PMC: PMC5223313